MedTrace Logo

Exercise on Expression of Heat Shock Protein 70 in Arterial Risk

NCT04743128 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-05-04

No results posted yet for this study

Summary

Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP), among which is Hsp70, to stimulate innate immunity and face stress.

Methods: This is a clinical trial where 260 individuals were evaluated by a screening test employing the Ankle-Arm Index (ABI), 220 of them were not within risk value (0.91 to 0.99 mmHg). In the clinical trial, 32 individuals were included. A control group and an experimental group were formed. Aerobic exercise intervention was performed for 12 weeks. The level of Hsp70 was evaluated, physical and clinical measurements were applied at the beginning and at the end of the trial.

Conditions

  • Peripheral Arterial Disease

Interventions

BEHAVIORAL

Exercise

The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.

Sponsors & Collaborators

  • Universidad Popular Autónoma del Estado de Puebla

    lead OTHER

Principal Investigators

  • Clara Luz Pérez Quiroga, MCs · Universidad Popular Autónoma del Estado de Puebla

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-03
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04743128 on ClinicalTrials.gov